Who is sponsoring NCT02952820?

NCT02952820 is sponsored by Eisai Inc..

What condition does NCT02952820 study?

NCT02952820 studies Insomnia Disorder.

What drugs are being tested in NCT02952820?

Interventions: lemborexant, Placebo.

What is the status of NCT02952820?

NCT02952820 is currently COMPLETED.

Last reviewed 2020-02-06 · How we verify

Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)

NCT02952820 PHASE3 COMPLETED Results posted

The key objectives of this study are to determine, using sleep diaries, whether lemborexant at the doses 5 milligrams (mg) and 10 mg is superior to placebo on subjective sleep onset, subjective sleep efficiency, and subjective sleep maintenance in participants with insomnia disorder.

Details

Lead sponsor	Eisai Inc.
Phase	PHASE3
Status	COMPLETED
Enrolment	971
Start date	Tue Nov 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Jan 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Insomnia Disorder

Interventions

lemborexant
Placebo

Countries

Italy, New Zealand, Finland, Japan, Germany, Poland, Mexico, South Korea, Romania, Canada, United States, Spain